Insights

Lockdowns are easing, but are CSL (ASX:CSL) shares out of the woods yet?

Have CSL shares turned a corner?
The post Lockdowns are easing, but are CSL (ASX:CSL) shares out of the woods yet? appeared first on The Motley Fool Australia. –

Across the country, lockdowns are indeed easing as we move towards Christmas and the end of 2021. But the CSL Limited (ASX: CSL) share price doesn’t quite look like it’s out of the woods just yet. That’s going off of this ASX 200 healthcare giant’s recent share price performance. CSL shares are, at the time of writing, trading at $310.96 each, up 1.16% for the day so far this Monday.

That puts CSL’s year to date gains at roughly 8.88%. That’s not awful, but when you consider the S&P/ASX 200 Index (ASX: XJO) is up around 13.4% for the same period, some shareholders might certainly be a little disappointed.

And when you look at CSL’s performance over the past year, things don’t get much better. CSL is down over the past 12 months by close to 0.3%. By contrast, the ASX 200 has put on a very healthy 16.6% over the same period. In fact, the CSL share price has barely done anything of note since January 2020. Back then, you could buy the same CSL shares for a very similar share price to what’s being asked today.

Now CSL shareholders probably aren’t used to this kind of share price malaise. This was a company that seemed to grow by double-digits every single year before last year, after all. In 2017, CSL shares went up by roughly 40%. In 2018, it was 32% and 2019 saw them appreciate by a whopping 50% or so.

So what’s going on here?

CSL share price has a year to forget, but is it back to the races?

Well, CSL was a company that struggled in the face of the coronavirus pandemic. Its plasma collections business suffered enormously due to global lockdowns while a promising vaccine candidate that CSL developed with the University of Queensland failed to get off the ground.

But that’s the past. So what does the future of the CSL share price look like?

Well, in some good news for investors, one broker has recently upgraded its view on CSL. As my Fool colleague Brendan covered last week, brokers at Macquarie Group Ltd (ASX: MQG) recently upgraded CSL shares to “outperform” from “neutral”, with a 12-month share price target of $338 per share. That implies a potential 12-month upside of close to 10%.

Macquarie believes the headwinds that have been buffeting CSL shares recently are easing. It points to the easing of disruptions in the US plasma collection market and reckons CSL’s new collection platform “may present upside for the group”.

At the current CSL share price of $310.96, this ASX 200 healthcare company has a market capitalisation of $141.6 billion, a price-to-earnings (P/E) ratio of 43.5 and a dividend yield of 0.95%.

The post Lockdowns are easing, but are CSL (ASX:CSL) shares out of the woods yet? appeared first on The Motley Fool Australia.

Should you invest $1,000 in CSL right now?

Before you consider CSL, you’ll want to hear this.

Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and CSL wasn’t one of them.

The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.

*Returns as of August 16th 2021

More reading

Leading brokers name 3 ASX shares to buy today

ASX 200 (ASX:XJO) midday update: Incitec Pivot and Mesoblast jump, NAB drops

ASX 200 lithium shares in focus amid China supply shortage

5 things to watch on the ASX 200 on Monday

These were the best performing ASX 200 shares last week

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of and has recommended CSL Ltd. The Motley Fool Australia owns shares of and has recommended Macquarie Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!